5月13日,诺诚健华发布2025年一季度报,报告期内实现营收3.81亿元,同比增长129.92%;净利润达到0.18亿元,同比增长112.62%,当季度实现盈利。此外,毛利率比上年同期提高5.1个百分点,达到90.5%。 诺诚健华成立于2015年,专注于恶性肿瘤、自免疾病等领域创新药物的研发及商业化。当前,诺诚健华共有多款在研产品并有2款产品进入商业化阶段。其中,2020年在我国上市的首款商业化...
Source Link5月13日,诺诚健华发布2025年一季度报,报告期内实现营收3.81亿元,同比增长129.92%;净利润达到0.18亿元,同比增长112.62%,当季度实现盈利。此外,毛利率比上年同期提高5.1个百分点,达到90.5%。 诺诚健华成立于2015年,专注于恶性肿瘤、自免疾病等领域创新药物的研发及商业化。当前,诺诚健华共有多款在研产品并有2款产品进入商业化阶段。其中,2020年在我国上市的首款商业化...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.